Potsdam/ Hanover, November 5, 2021 – In collaboration with Prof. Dr. Matthias Karst from the Hannover Medical School (MHH) iuvo Therapeutics GmbH (iuvo Therapeutics or iuvo) is organizing a practice-relevant online training course for doctors on cannabis‑based medicine (CBM) on November 17, 2021.
The advanced training course “Insights into an efficient therapy with cannabis-based pharmaceuticals”, certified with 2 CME points by the State Medical Association of North Rhine, will take place online on November 17, 2021 at 5 p.m. and is primarily aimed at doctors from all specialist groups (except dentistry and veterinary medicine) and secondarily to pharmaceutical specialists. The focus is on the background and findings on therapy with CBM on patients with chronic pain. Another important aspect are the applications on health insurance coverage. For this purpose, case studies are discussed with the participants. More than a hundred guests are expected for the one-and-a-half hour training course. It takes place via the widespread application Zoom, which is compatible with many technical end devices (see link below).
“The application for reimbursement of costs with a rejection rate of around 40 percent makes therapy with cannabis-based medicine more difficult,” explains Prof. Dr. Karst from the MHH, “That is why it is so important to exchange ideas intensively and practically with colleagues as part of this online training and to share experiences.”
It is the third online training this year that iuvo has organized in cooperation with Prof. Dr. Karst. The past training courses met high demand from medical professionals with several hundred registrations.
“We regard the positive feedback from the doctors on the training courses as clear confirmation that we can continue to establish cannabis therapy together with experts in this field in the medical world and thus ultimately ensure that patients are supplied with CBM”, says Tibor Rietzsch Junge, Head of Marketing and Public Relations at iuvo.
Doctors and pharmaceutical specialists can register for the training under the following link:https://zoom.us/webinar/register/8616361096849/WN_6UWN9n_4QmiGEWFCdY7jaQ
Abstract of the training
While findings from meta-analyzes attribute only a low to moderate effectiveness to CBM in chronic non-tumor pain, the experiences of many patients point in the opposite direction. This discrepancy is mainly explained by the fact that the outcome parameters commonly used in randomized clinical studies do not adequately reflect the potential of the positive changes triggered by CBM. The reservation of approval anchored in the Cannabis-as-Medicine Act means that the health insurance coverage will continue to be refused in around 40% of all cases and not just “in justified exceptional cases”. In particular, the argument “lack of evidence” cited by the health insurances goes against the intention of the legislature, which deliberately did not specify any indication, and against the understanding of evidence-based medicine (EBM), which is based on findings from data-based medicine and the experience of the practitioners and the patients. In this area of tension between findings about therapy with CBM (especially for chronic pain) and socio-medical requirements, current information and experiences are shared.
About iuvo Therapeutics
The pharmaceutical company iuvo Therapeutics, founded in 2017 and headquartered in Düsseldorf, pursues the goal of reliably supplying patients in Europe with cannabis-based medicine of the highest quality. To achieve this goal, iuvo, as an independent importer, manufacturer and wholesaler, constantly expands its manufacturer partnerships and supply chains, which have been successfully GDP and GMP certified for years. Pharmacies and a selection of pharmaceutical wholesalers are part of iuvo‘s distribution network.
The company develops its pharmaceuticals based on the state of science and in cooperation with experts in cannabis therapy, supports doctors and pharmaceutical specialists through recognized, scientific training courses. iuvo Therapeutics is an active member of the Federal Association of Pharmaceutical Cannabinoid Companies.
